3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...
May 3–5, 2026 – Basel, Switzerland
⚛️ Where Global Biotech Comes Together
Veristat is pleased to attend Swiss Biotech Day 2026, one of Europe’s leading biotechnology conferences, bringing together innovators, investors, and development leaders at the heart of Switzerland’s life sciences ecosystem.
As partnerships form and programs take shape, early alignment and clear development strategy play a critical role in setting therapies up for success. And as sponsors advance through early and mid-stage development, the margin for error narrows. Progress depends on disciplined clinical planning, strong statistical foundations, and regulatory clarity that holds up under scrutiny.
Our team looks forward to connecting with biotech leaders to discuss how Veristat helps move complex programs forward while making every dollar of development capital count.
👥 Meet the Veristat Team at Swiss Biotech Day
Connect with us at Booth 19 to explore how Veristat’s scientific leadership and focused capabilities support confident decisions and efficient progress across clinical and regulatory milestones.
📅 Schedule a meeting in advance
Complete the form on this page to reserve time with our team. We welcome the opportunity to learn about your upcoming programs and explore how Veristat can support your development strategy.
💡 Our Areas of Focus
Veristat’s work centers on the capabilities sponsors need most as programs move toward key development and regulatory milestones:
-
Phase I–II Clinical Development
-
Biostatistics and Data-Driven Evidence
-
Global Regulatory Strategy and Submissions
Together, these capabilities help sponsors move from study design to submission with clarity, reduce rework, and accelerate progress toward patients while preserving development capital.
Schedule A Meeting
Meet with us at Swiss Biotech Day
Basel, Switzerland | Booth 19
9 min read
Monthly FDA Guidance and Regulatory News Review - March 2026
Apr 6, 2026 Veristat Blog
March 2026 regulatory updates underscore newly published final and draft guidances focused on real-world data, safety...